Pharmacokinetics and pharmacodynamics of lanadelumab in patients with HAE in the phase 3 HELP study

被引：0

作者：

Cicardi, M. ^{[1
]}

Shennak, M. ^{[2
]}

Zaragoza-Urdaz, R. H. ^{[3
]}

Wang, Y. ^{[4
]}

Lu, P. ^{[4
]}

机构：

[1] Univ Milan, Dept Biomed & Clin Sci, ASST Fatebenefratelli Sacco, Luigi Sacco, Milan, Italy

[2] Triumpharma, Amman, Jordan

[3] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA

[4] Shire, Lexington, MA USA

来源：

ALLERGY | 2018年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

1428

引用

页码：722 / 722

页数：1

共 50 条

[31] SUBCUTANEOUS SELF-ADMINISTRATION OF LANADELUMAB FOR PROPHYLACTIC TREATMENT IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE)
Lumry, W.
Busse, P.
Lu, P.
Jain, G.
Nurse, C.
Maurer, M.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S57 - S57
[32] Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study
Buttgereit, Thomas
Vera, Carolina
Weller, Karsten
Gutsche, Annika
Grekowitz, Eva Maria
Aykanat, Seda
Wahn, Volker
Krueger, Renate
Maurer, Marcus
Magerl, Markus
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (10) : 3744 - 3751
[33] REAL-WORLD OUTCOMES IN PATIENTS WITH HAE RECEIVING LANADELUMAB LONG-TERM PROPHYLAXIS FOR 3 YEARS OR LONGER
Lumry, W.
Davis-Lorton, M.
Soteres, D.
Earl, L.
Wynne-Cattanach, K.
Sing, K.
Juethner, S.
Schultz, B.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S29 - S29
[34] Efficacy of lanadelumab at fixed and modified dosing regimens in patients aged 2 to <12 years old with hereditary angioedema (HAE) in the phase 3, open-label, multicenter SPRING Study
Lumry, William
Bernstein, Jonathan
Tachdjian, Raffi
Wedner, H. James
Yang, William
Maurer, Marcus
Martinez-Saguer, Inmaculada
Farkas, Henriette
Nurse, Christina
Yu, Ming
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB140 - AB140
[35] Pharmacokinetics and pharmacodynamics modeling of ritonavir boosted lonafarnib therapy in HDV patients: A phase 2 LOWRHDV-3 study
Dubey, P.
Koh, C.
Surana, P.
Uprichard, S.
Han, M. A. T.
Fryzek, N.
Subramanya, G.
Kapuria, D.
Etzion, O.
Takyar, V.
Rotman, Y.
Yurdaydin, C.
Glenn, J.
Cotler, S.
Heller, T.
Dahari, H.
JOURNAL OF HEPATOLOGY, 2018, 68 : S508 - S508
[36] STUDY OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF PHENOBARBITAL IN EXPERIMENT AND EPILEPTIC PATIENTS
MARTIROSYAN, VV
BOICHENKO, VS
DYATCHINA, LI
FARMAKOLOGIYA I TOKSIKOLOGIYA, 1982, 45 (03): : 92 - 93
[37] LANADELUMAB EXPOSURE DURING STEADY STATE: ACHIEVEMENT OF EFFECTIVE CONCENTRATIONS IN PATIENTS IN THE HELP STUDY
Zuraw, B.
Cicardi, M.
Jacobs, J.
Longhurst, H.
Lu, P.
Manning, M.
Shennak, M.
Soteres, D.
Wang, Y.
Zaragoza-Urdaz, R.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S37 - S37
[38] Pharmacokinetics and pharmacodynamics of tenecteplase: Results from a phase II study in patients with acute myocardial infarction
Modi, NB
Fox, NL
Clow, FW
Tanswell, P
Cannon, CP
Van de Werf, F
Braunwald, E
JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 40 (05) : 508 - 515
[39] Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer
Bruno, R
Hille, D
Riva, A
Vivier, N
Huinnink, WWTB
van Oosterom, AT
Kaye, SB
Verweij, J
Fossella, FV
Valero, V
Rigas, JR
Seidman, AD
Chevallier, B
Fumoleau, P
Burris, HA
Ravclin, PM
Sheiner, LB
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) : 187 - 196
[40] Lanadelumab efficacy and safety after switching from androgens: analysis of the phase 3 HELP and HELP OLE studies for hereditary angioedema
Lumry, William
Johnston, Douglas
Riedl, Marc
Choudhry, Zia
Nurse, Christina
Yegin, Ashley
Juethner, Salome
Banerji, Aleena
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB166 - AB166

← 1 2 3 4 5 →